1. Morris JC, Drazner M, Fulling K, Grant EA, Goldring J. Clinical and pathological aspects of parkinsonism in Alzheimer's disease. Arch Neurol. 1989. 46:651–657.
Article
2. Stern Y, Albert M, Brandt J, Jacobs DM, Tang MX, Marder K, et al. Utility of extrapyramidal signs and psychosis as predictors of cognitive and functional decline, nursing home admission, and death in Alzheimer's disease: prospective analyses from the predictors study. Neurology. 1994. 44:2300–2307.
Article
3. Lopez OL, Wisnieski SR, Becker JT, Boller F, DeKosky ST. Extrapyramidal signs in patients with probable Alzheimer disease. Arch Neurol. 1997. 54:969–975.
Article
4. Murray AM, Weihmueller FB, Marshall JF, Hurting HI, Gottleib GL, Joyce JN. Damage to systems differs between parkinson's disease and Alzheimer's disease with parkinsonism. Ann Neurol. 1995. 37:300–312.
Article
5. Piggott MA, Marshall EF, Thomas N, Lloyd S, Court JA, Jaros E, et al. Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and parkinson's disease: rostrocaudal distribution. Brain. 1999. 122:1449–1468.
Article
6. Liu Y, Stern Y, Chun MR, Jacobs DM, Yau P, Goldman JE. Pathological correlates of extrapyramidal signs in Alzheimer's disease. Ann Neurol. 1997. 41:368–374.
Article
7. Perl DP, Olanow CW, Calne D. Alzheimer's disease and Parkinson's disease: distinct entities or extremes of spectrum of neurodegeneration? Ann Neurol. 1998. 44:Suppl 1. S19–S31.